Russeva M - Search Results

1

Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer.

Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Yuan QA, et al. Among authors: russeva m. Mol Cancer Ther. 2006 Aug;5(8):2096-105. doi: 10.1158/1535-7163.MCT-06-0115. Mol Cancer Ther. 2006. PMID: 16928831

2

Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.

Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Horak E, et al. Among authors: russeva m. Cancer Biother Radiopharm. 2005 Dec;20(6):603-13. doi: 10.1089/cbr.2005.20.603. Cancer Biother Radiopharm. 2005. PMID: 16398612

3

Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning.

Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP. Yuan QA, et al. Among authors: russeva m. Cancer Immunol Immunother. 2008 Mar;57(3):367-78. doi: 10.1007/s00262-007-0376-2. Epub 2007 Aug 4. Cancer Immunol Immunother. 2008. PMID: 17676323 Free PMC article.

4

Radioimmunotherapy with engineered antibodies.

Russeva MG, Adams GP. Russeva MG, et al. Expert Opin Biol Ther. 2004 Feb;4(2):217-31. doi: 10.1517/14712598.4.2.217. Expert Opin Biol Ther. 2004. PMID: 14998779 Review.

5

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Robinson MK, et al. Among authors: russeva m. Br J Cancer. 2008 Nov 4;99(9):1415-25. doi: 10.1038/sj.bjc.6604700. Epub 2008 Oct 7. Br J Cancer. 2008. PMID: 18841159 Free PMC article.

6

Tpl-2 induces apoptosis by promoting the assembly of protein complexes that contain caspase-9, the adapter protein Tvl-1, and procaspase-3.

Patriotis C, Russeva MG, Lin JH, Srinivasula SM, Markova DZ, Tsatsanis C, Makris A, Alnemri ES, Tsichlis PN. Patriotis C, et al. Among authors: russeva mg. J Cell Physiol. 2001 May;187(2):176-87. doi: 10.1002/jcp.1066. J Cell Physiol. 2001. PMID: 11267997

7

Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patients with pulmonary thromboembolism and deep venous thrombosis.

Boyanovsky B, Russeva M, Ganev V, Penev M, Baleva M. Boyanovsky B, et al. Among authors: russeva m. Blood Coagul Fibrinolysis. 2001 Dec;12(8):639-42. doi: 10.1097/00001721-200112000-00004. Blood Coagul Fibrinolysis. 2001. PMID: 11734663

8

Protein C activity in patients with antiphospholipid syndrome.

Boyanovski B, Russeva M, Dobreva G, Ganev V, Mladenova A, Peicheva V, Nikolov K, Baleva M. Boyanovski B, et al. Among authors: russeva m. J Clin Rheumatol. 2000 Oct;6(5):239-43. doi: 10.1097/00124743-200010000-00002. J Clin Rheumatol. 2000. PMID: 19078479

9

A simple method for detection of factor V R506Q (Leiden) mutation in dried blood spots.

Russeva MG, Janakiev PJ, Kirov SA, Paskaleva ID, Kremensky IM, Penner JA, Hassouna HS, Ganev VS. Russeva MG, et al. Clin Chim Acta. 1999 Jun 15;284(1):89-92. doi: 10.1016/s0009-8981(99)00024-8. Clin Chim Acta. 1999. PMID: 10437646 No abstract available.

10

An experimental study of the effect of low level helium-neon laser irradiation on the reparative processes of the cornea after perforative injury.

Zapryanov Z, Koev K, Tanev V, Russeva M. Zapryanov Z, et al. Among authors: russeva m. Folia Med (Plovdiv). 1990;32(2):39-44. Folia Med (Plovdiv). 1990. PMID: 2103917 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page